<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tivantinib (ARQ 197) is an orally administered, selective small molecule that inhibits mesenchymal-epithelial transition factor (MET) via a novel, ATP-independent binding mechanism </plain></SENT>
<SENT sid="1" pm="."><plain>Preclinical studies demonstrated that tivantinib has a broad-spectrum anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity, especially in cells expressing high levels of MET </plain></SENT>
<SENT sid="2" pm="."><plain>A randomized Phase II study in second-line <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> showed statistically significant improvement in time to progression with tivantinib compared to a placebo </plain></SENT>
<SENT sid="3" pm="."><plain>Noteworthy, a significant pronounced benefit in time to progression and overall survival was observed in MET-high patients </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, MET expression was defined as a negative prognostic factor </plain></SENT>
<SENT sid="5" pm="."><plain>The most frequent adverse events were hematologic events </plain></SENT>
<SENT sid="6" pm="."><plain>A Phase III study in the MET-high <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> is actively recruiting patients </plain></SENT>
<SENT sid="7" pm="."><plain>Phase II and III studies in <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> are ongoing </plain></SENT>
</text></document>